This document discusses various methods for calculating Wasserstein distance between probability distributions, including:
- Sliced Wasserstein distance, which projects distributions onto lower-dimensional spaces to enable efficient 1D optimal transport calculations.
- Max-sliced Wasserstein distance, which focuses sampling on the most informative projection directions.
- Generalized sliced Wasserstein distance, which uses more flexible projection functions than simple slicing, like the Radon transform.
- Augmented sliced Wasserstein distance, which applies a learned transformation to distributions before projecting, allowing more expressive matching between distributions.
These sliced/generalized Wasserstein distances have been used as loss functions for generative models with promising
This document discusses various methods for calculating Wasserstein distance between probability distributions, including:
- Sliced Wasserstein distance, which projects distributions onto lower-dimensional spaces to enable efficient 1D optimal transport calculations.
- Max-sliced Wasserstein distance, which focuses sampling on the most informative projection directions.
- Generalized sliced Wasserstein distance, which uses more flexible projection functions than simple slicing, like the Radon transform.
- Augmented sliced Wasserstein distance, which applies a learned transformation to distributions before projecting, allowing more expressive matching between distributions.
These sliced/generalized Wasserstein distances have been used as loss functions for generative models with promising
Presentation slide for AI seminar at Artificial Intelligence Research Center, The National Institute of Advanced Industrial Science and Technology, Japan.
URL (in Japanese): https://www.airc.aist.go.jp/seminar_detail/seminar_046.html
This document summarizes research using surface-enhanced Raman spectroscopy (SERS) to analyze the structural differences between amyloid beta 40, 42, and 42 fibril proteins involved in Alzheimer's disease. The study deposited amyloid beta solutions onto a graphene-coated gold nanoparticle substrate to obtain Raman spectra. Principal component analysis of the spectra showed the platform can differentiate amyloid beta 40, 42, and 42 fibril structures. This technique provides a method to fully characterize amyloid beta from the monomeric to fibril stages and could help understand Alzheimer's disease progression.
Presentation slide for AI seminar at Artificial Intelligence Research Center, The National Institute of Advanced Industrial Science and Technology, Japan.
URL (in Japanese): https://www.airc.aist.go.jp/seminar_detail/seminar_046.html
This document summarizes research using surface-enhanced Raman spectroscopy (SERS) to analyze the structural differences between amyloid beta 40, 42, and 42 fibril proteins involved in Alzheimer's disease. The study deposited amyloid beta solutions onto a graphene-coated gold nanoparticle substrate to obtain Raman spectra. Principal component analysis of the spectra showed the platform can differentiate amyloid beta 40, 42, and 42 fibril structures. This technique provides a method to fully characterize amyloid beta from the monomeric to fibril stages and could help understand Alzheimer's disease progression.
Alzheimer's disease is a progressive neurodegenerative disease that causes loss of neurons and synapses in the brain. The main pathological hallmarks are extracellular amyloid beta plaques and intraneuronal neurofibrillary tangles. Current treatments only temporarily improve cognitive symptoms but do not stop progression of the disease. New treatments are needed to both maintain cognitive abilities and halt the underlying disease process.
Alzheimer's disease is a progressive brain disorder that destroys memory and cognitive skills. Dr. Alois Alzheimer first described it in 1906 after examining a woman with dementia. The disease is characterized by beta-amyloid plaques and neurofibrillary tangles in the brain. Current treatments aim to improve symptoms but do not stop the underlying disease process. Researchers are exploring therapies targeting amyloid and tau proteins as well as other mechanisms to find a cure.
